Martin William Dewhurst
CIK: 0002108597
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Dewhurst Martin William
Dewhurst Martin William (SEC CIK 0002108597) files insider reports with the SEC as Director of NovaBridge Biosciences (NBP) and Director of Turn Therapeutics Inc. (TTRX).
Signal8 holds 4 ownership filings by Dewhurst Martin William (2 Form 3, 2 Form 4), filed between Feb 4, 2026 and Sep 10, 2026. Those filings report 2 transactions, from Jan 7, 2026 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dewhurst Martin William's filings is in ROCKVILLE, MD.
Recent filings by Dewhurst Martin William
Other insiders filing for NovaBridge Biosciences (NBP)
- Silberstein Charles, Chief Financial Officer
- Woo Ian Ying, Director
- Dennis Phillip Andrew, Chief Medical Officer
- Cao Sean Wuxiong, Chief Bus. Development Officer
- Xu Cong Claire, EVP, Clinical Development
- Lenz Robert A., Director